NASDAQ:JSPRW Jasper Therapeutics (JSPRW) Stock Price, News & Analysis $0.08 +0.02 (+26.27%) As of 09/16/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Jasper Therapeutics Stock (NASDAQ:JSPRW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0850-Day Range$0.05▼$0.1152-Week Range$0.04▼$0.25Volume16,199 shsAverage Volume7,872 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on the development of targeted protein conjugates for the treatment of cancer and other serious diseases. The company’s research and development efforts center on its proprietary Modular Targeting Conjugate (MTC) platform, which enables the fusion of targeting ligands—such as antibody fragments and affibodies—with diverse therapeutic payloads. The MTC platform supports the rapid generation and optimization of novel therapeutics by combining binding domains with cytotoxic agents, radionuclides and immunomodulators. Jasper’s lead preclinical candidate, a carcinoembryonic antigen (CEA)-targeted conjugate, has demonstrated promising tumor specificity in preclinical oncology models. Beyond oncology, the company is exploring applications in immuno-oncology and other high-unmet-need areas. Jasper conducts its research and development activities primarily in North America, with initiatives to extend its clinical programs to Europe and other regions. The company collaborates with academic research institutions and biopharmaceutical partners to advance its pipeline and manufacturing capabilities. Led by a management team of experienced life sciences professionals, Jasper Therapeutics aims to translate its modular platform technology into differentiated therapies for patients worldwide.AI Generated. May Contain Errors. Read More Receive JSPRW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPRW Stock News HeadlinesTD Cowen Remains a Buy on Jasper Therapeutics (JSPR)August 15, 2025 | theglobeandmail.comJasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive PressuresAugust 15, 2025 | msn.com2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.September 17 at 2:00 AM | Crypto Swap Profits (Ad)Jasper Therapeutics Inc. Stock Grades | JSPR | Barron'sJuly 12, 2025 | barrons.comBMO Capital Downgrades Jasper Therapeutics (JSPR)July 9, 2025 | msn.comWilliam Blair Downgrades Jasper Therapeutics (JSPR)July 8, 2025 | msn.comJasper Therapeutics Shares Plunge Premarket as Briquilimab Issues Upend StudiesJuly 7, 2025 | marketwatch.comJasper Therapeutics stock plunges after manufacturing issues derail clinical trialsJuly 7, 2025 | in.investing.comSee More Headlines JSPRW Stock Analysis - Frequently Asked Questions How have JSPRW shares performed this year? Jasper Therapeutics' stock was trading at $0.2096 at the beginning of 2025. Since then, JSPRW stock has decreased by 62.2% and is now trading at $0.0793. How do I buy shares of Jasper Therapeutics? Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPRW CIK1788028 WebN/A Phone650-549-1400FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:JSPRW) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.